Abstract: The present invention provides TCRs having an affinity (KD) of less than or equal to 1 ?M, and/or an off-rate (koff) of 1×10?3S?1 or slower, for the SLYNTVATL-HLA-A*0201 complex provided that when the said TCR is presented by cell and comprises SEQ ID NOS:1 and 2, the cell is not a native T cell. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting HIV infected cells presenting that complex.

Abstract: The present invention provides a soluble bifunctional protein comprising an association between a T cell receptor and a superantigen. Also provided are therapeutic compositions comprising said bifunctional proteins and methods for the use thereof.

Abstract: Compounds of formula (I) are CD80 inhibitors, and of value for immunomodulation, e.g. in rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis: wherein Y is —CH2—, —CH2CH2—, or CH2CH2CH2—; R1 represents H; F; methyl, trifuoromethyl, methoxy or triflioromethoxy; R3 represents H; F; CI; Br; NO2; CN; C1C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(?O) NR6R7—NR7C(?O)R6, NR7C(?O)OR6, NHC(?O) or NHC(?S)NR7R6 wherein R6 and R7 are as defined in the specification and X represents a bond or a divalent radical as defined in the specification.

Abstract: A multivalent T cell receptor (TCR) complex comprising at least two TCRs, linked by a non-peptidic polymer chain or a peptidic linker sequence. Preferably the TCR complex comprises TCR heterodimers having a non-native disulfide bond between constant domain residues, said TCRs being linked via an optionally substituted, polyalkylene glycol linker. Therapeutic agents such as cytotoxic drugs may be attached to such complexes for targeted cell delivery. Such TCR complexes may be used in the diagnosis or treatment of cancer, infectious disease, or autoimmune disease.